(608) 217-5587 alexv@plumbpharma.com

The Market

Beachhead Market Opportunity

Advanced Quantload Platform (AQL™)

Plumb Pharmaceuticals, Inc. is commercializing a platform technology for super extended-release drug delivery. Medications developed using the company’s AQL technology have release rates measured in months, not days, enabling (for example) the provision of an entire course of antibiotics with a single injection, or continuous, longer-term relief from chronic pain and addiction.

Advanced Quantload (AQL™) Platform Technology

Step 1

Step 1

Loading base (B) is captured efficiently and residual external loading base is removed after liposome
preparation.

Step 2

Step 2

Drug (R,) is loaded into the liposome by "swapping" with loading base

Step 3

Step 3

Leakage of residual loading base delays release
of drug.

AQL Platform Advantage

Plumb’s first product, an AQL-Naltrexone anti-opioid drug formulation, will provide the longest-acting, injectable medication assisted therapy option on the market, with an effective duration of 2 months. Plumb has validated the market need, product-market fit, and customer buying processes through more than 170 direct customer interactions. This competitive advantage is protected by two issued patents and manufacturing trade secrets owned exclusively by Plumb.